Literature DB >> 22621397

Irreversible protein kinase inhibitors: balancing the benefits and risks.

Tjeerd Barf1, Allard Kaptein.   

Abstract

Mesh：

Substances：

Year:  2012        PMID： 22621397     DOI： 10.1021/jm3003203

Source DB:  PubMed          Journal:  J Med Chem        ISSN： 0022-2623            Impact factor:   7.446


× No keyword cloud information.
  67 in total

Review 1.  Targeting protein kinases with selective and semipromiscuous covalent inhibitors.

Authors:  Rand M Miller; Jack Taunton
Journal:  Methods Enzymol       Date:  2014       Impact factor: 1.600

2.  Selective Covalent Targeting of Mutated EGFR(T790M) with Chlorofluoroacetamide-Pyrimidines.

Authors:  Mami Sato; Hirokazu Fuchida; Naoya Shindo; Keiko Kuwata; Keisuke Tokunaga; Guo Xiao-Lin; Ryo Inamori; Keitaro Hosokawa; Kosuke Watari; Tomohiro Shibata; Naoya Matsunaga; Satoru Koyanagi; Shigehiro Ohdo; Mayumi Ono; Akio Ojida
Journal:  ACS Med Chem Lett       Date:  2020-04-08       Impact factor: 4.345

Review 3.  Developing irreversible inhibitors of the protein kinase cysteinome.

Authors:  Qingsong Liu; Yogesh Sabnis; Zheng Zhao; Tinghu Zhang; Sara J Buhrlage; Lyn H Jones; Nathanael S Gray
Journal:  Chem Biol       Date:  2013-02-21

Review 4.  Protein-ligand (un)binding kinetics as a new paradigm for drug discovery at the crossroad between experiments and modelling.

Authors:  M Bernetti; A Cavalli; L Mollica
Journal:  Medchemcomm       Date:  2017-01-30       Impact factor: 3.597

5.  Discovery of a Type III Inhibitor of LIM Kinase 2 That Binds in a DFG-Out Conformation.

Authors:  Nicole C Goodwin; Giovanni Cianchetta; Hugh A Burgoon; Jason Healy; Ross Mabon; Eric D Strobel; Jason Allen; Shuli Wang; Brian D Hamman; David B Rawlins
Journal:  ACS Med Chem Lett       Date:  2014-08-07       Impact factor: 4.345

6.  Inhibition of Mcl-1 through covalent modification of a noncatalytic lysine side chain.

Authors:  Gizem Akçay; Matthew A Belmonte; Brian Aquila; Claudio Chuaqui; Alexander W Hird; Michelle L Lamb; Philip B Rawlins; Nancy Su; Sharon Tentarelli; Neil P Grimster; Qibin Su
Journal:  Nat Chem Biol       Date:  2016-09-05       Impact factor: 15.040

Review 7.  Selective and Effective: Current Progress in Computational Structure-Based Drug Discovery of Targeted Covalent Inhibitors.

Authors:  Giulia Bianco; David S Goodsell; Stefano Forli
Journal:  Trends Pharmacol Sci       Date:  2020-11-02       Impact factor: 14.819

Review 8.  Non-kinase targets of protein kinase inhibitors.

Authors:  Lenka Munoz
Journal:  Nat Rev Drug Discov       Date:  2017-03-10       Impact factor: 84.694

9.  Oxopyrido[2,3-d]pyrimidines as Covalent L858R/T790M Mutant Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors.

Authors:  Ryan P Wurz; Liping H Pettus; Kate Ashton; James Brown; Jian Jeffrey Chen; Brad Herberich; Fang-Tsao Hong; Essa Hu-Harrington; Tom Nguyen; David J St Jean; Seifu Tadesse; David Bauer; Michele Kubryk; Jinghui Zhan; Keegan Cooke; Petia Mitchell; Kristin L Andrews; Faye Hsieh; Dean Hickman; Nataraj Kalyanaraman; Tian Wu; Darren L Reid; Edward K Lobenhofer; Dina A Andrews; Nancy Everds; Roberto Guzman; Andrew T Parsons; Simon J Hedley; Jason Tedrow; Oliver R Thiel; Matthew Potter; Robert Radinsky; Pedro J Beltran; Andrew S Tasker
Journal:  ACS Med Chem Lett       Date:  2015-07-27       Impact factor: 4.345

10.  The human kinome and kinase inhibition.

Authors:  Krisna C Duong-Ly; Jeffrey R Peterson
Journal:  Curr Protoc Pharmacol       Date:  2013-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.